Administrative/Statistics/Imaging Core

行政/统计/成像核心

基本信息

  • 批准号:
    8375082
  • 负责人:
  • 金额:
    $ 11.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-06-25 至 2014-05-31
  • 项目状态:
    已结题

项目摘要

The Administrative Part of Core A provides Dr. Schreiber protected time for scientific leadership and careful guidance of the Program Project. This leadership will be essential for achieving the goals of the program project that depend on integrating scientists with highly complementary but fundamentally different skills and operation modes and very diverse methodology and technology. Effective productive integration will depend on minimizing negative effects of the physical separation of the interacting scientists. This requires dedicated time from Dr. Schreiber for careful planning and using methods of easy interaction over long distances. For coordinating the scientific and technical activities of this program project, the Core will (i) organize a monthly steering committee meeting and research-in-progress meeting with the leaders of the four projects, the statistician and the core directors with careful planning of the agenda including distribution of data, manuscripts and papers to be discussed, (ii) organizes a more comprehensive quarterly meeting of all scientific and technical personnel involved in the program, (iii) prepare, distribute and maintain electronic files of reports, protocols and images and distribute relevant research articles, (iv) prepare and update existing databases for cell lines, gene constructs, monoclonal antibodies and vectors, and (v) monitor day-today expenses, support and organize the visits of one external scientific advisor and one external collaborator per year. The Statistics Part of Core A, provides a protected time to our statistician Dr. Karrison. This provides researchers with a highly experienced scholarly statistician who is dedicated to the success of this program project. This arrangement will give us much improved access to biostatistical consultation during the planning and execution and analysis stages of the proposed studies. The Imaging Part of Core A under the leadership of Dr. P. Charles Lin provides researchers with continued access to the first rate imaging institute at Vanderbilt for optical imaging using window chamber technology. The migration and localization of the fluorescent T cells or fluorochrome-tagged molecules to large well-established tumors will be monitored through a window opening on one side of these tumors using the Zeiss multiphoton laser scanning microscope LSM 510 META. The new META (Zeiss) spectral detectors resolve emissions from these different fluorescent dyes efficiently and exactly by providing linear spectral unmixing using specialized software. The microscopic imaging of the tumor microenvironment will give us detailed information on real time events and precise locality of cells or molecules injected into mice in the various models proposed.
核心A的管理部分为Schreiber博士提供了科学领导和谨慎的保护时间

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hans Schreiber其他文献

Hans Schreiber的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hans Schreiber', 18)}}的其他基金

CD8+ T Cells and Immunological Tumor Regression
CD8 T 细胞和免疫肿瘤消退
  • 批准号:
    6609963
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
Three Laser BD Digital LSR
三激光BD数字LSR
  • 批准号:
    6580559
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
Administrative/Statistics/Imaging Core
行政/统计/成像核心
  • 批准号:
    8270394
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
Cancer Cells and Stroma: Eradication of Established Cancer by CD8+ T
癌细胞和基质:通过 CD8 T 根除已形成的癌症
  • 批准号:
    8375073
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
CD8+ T Cells and Immunological Tumor Regression
CD8 T 细胞和免疫肿瘤消退
  • 批准号:
    7229578
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
CD8+ T cells and Immunological Tumor Regression
CD8 T 细胞和免疫肿瘤消退
  • 批准号:
    7446448
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
CD8+ T Cells and Immunological Tumor Regression
CD8 T 细胞和免疫肿瘤消退
  • 批准号:
    6900349
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
CD8+ T cells and Immunological Tumor Regression
CD8 T 细胞和免疫肿瘤消退
  • 批准号:
    8270396
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
Cancer Cells and Stroma: Eradication of Established Cancer by CD8+ T
癌细胞和基质:通过 CD8 T 根除已形成的癌症
  • 批准号:
    8081108
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:
CD8+ T Cells and Immunological Tumor Regression
CD8 T 细胞和免疫肿瘤消退
  • 批准号:
    7118501
  • 财政年份:
    2003
  • 资助金额:
    $ 11.14万
  • 项目类别:

相似海外基金

AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 11.14万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 11.14万
  • 项目类别:
Basic studies of low-dose cisplatin-based concurrent chemoradiotherapy on human cervix carcinoma cells (HeLa cell line)
小剂量顺铂同步放化疗对人宫颈癌细胞(HeLa细胞系)的基础研究
  • 批准号:
    17K16425
  • 财政年份:
    2017
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Differential expression of cell adhesion molecule of CD133-positive / negative cells derived from oral cancer cell line and diagnostic treatment targeting it
口腔癌细胞系CD133阳性/阴性细胞细胞粘附分子的差异表达及针对其的诊断治疗
  • 批准号:
    17K17251
  • 财政年份:
    2017
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Deveopment of methods to establish cell-line of parathyroid cells
甲状旁腺细胞系建立方法的开发
  • 批准号:
    16K09628
  • 财政年份:
    2016
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SBIR Phase II: A novel multicolor cell line engineering platform that enables high-throughput microscopy-based screening of living cells for drug discovery
SBIR II 期:一种新型多色细胞系工程平台,可实现基于高通量显微镜的活细胞筛选以用于药物发现
  • 批准号:
    1632576
  • 财政年份:
    2016
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Standard Grant
The analysis of heme synthesis mechanism and the establishment of disease model cells for X-linked sideroblastic anemia using an immortalized human erythroid cell line.
利用永生化人红细胞系分析血红素合成机制并建立X连锁铁粒幼细胞贫血疾病模型细胞。
  • 批准号:
    15K19539
  • 财政年份:
    2015
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
SBIR Phase I: A novel multicolor cell line engineering platform that enables high-throughput microscopy-based screening of living cells for drug discovery
SBIR 第一阶段:一种新型多色细胞系工程平台,可实现基于高通量显微镜的活细胞筛选以用于药物发现
  • 批准号:
    1448764
  • 财政年份:
    2015
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Standard Grant
Elucidation of characteristic alterations of spermatogonial stem cells in testicular cancer and application to genome-based drug discovery using novel cell line
阐明睾丸癌中精原干细胞的特征改变以及使用新型细胞系在基于基因组的药物发现中的应用
  • 批准号:
    26462421
  • 财政年份:
    2014
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of lacrimal gland epithelial cell line for the evaluation of lacrimal gland cells
泪腺上皮细胞系的建立用于泪腺细胞的评价
  • 批准号:
    24592650
  • 财政年份:
    2012
  • 资助金额:
    $ 11.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了